Entera Bio (ENTX) Net Cash Flow (2021 - 2026)

Entera Bio (ENTX) has reported Net Cash Flow for 6 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow fell 124.82% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 175.81% YoY) and the FY2025 annual result came in at $6.2 million, up 365.8% from the prior year.
• Net Cash Flow declined to -$3.0 million in Q1 2026 per ENTX's latest filing, from -$1.7 million in the prior quarter.
• Over the last five years, Net Cash Flow for ENTX reached as high as $11.9 million in Q1 2025 and fell as low as -$4.8 million in Q1 2022.
• A 5-year average of -$761823.5 and a median of -$1.7 million in 2025 frame the typical range for Net Cash Flow.
• The largest YoY upside for Net Cash Flow was 750.93% in 2025 against a maximum downside of 1337.82% in 2025.
• Year by year, Net Cash Flow stood at -$2.0 million in 2022, then soared by 269.27% to $3.4 million in 2023, then plunged by 48.75% to $1.7 million in 2024, then sank by 196.51% to -$1.7 million in 2025, then plunged by 75.56% to -$3.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$3.0 million, -$1.7 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.